ThomasNet News Logo
Sign Up | Log In | ThomasNet Home | Promote Your Business

Preanalytics Instrument automates sample processing.

Print | 
Email |  Comment   Share  
December 10, 2013 - Reducing hands-on time for delivering test results, cobas p 480 automates uncapping and recapping of primary sample vials used for liquid-based cytology (LBC) and molecular assays run on cobas® 4800 System. Preprocessing steps, including vial cap removal, vortexing, and barcode quality checks, are automated, reducing risk of sample mix-up, cross contamination, and user error. Also, primary vials can be loaded directly onto cobas® 4800 System without need to aliquot into secondary vial.

Roche Launches Cobas p 480 Instrument for High-Volume, Automated Preanalytic Processing of Primary Vial Molecular Diagnostic Samples

Roche Bioscience
3401-T Hillview Ave.
Palo Alto, CA, 94304

Press release date: December 2, 2013

-- New system reduces laboratory hands-on time by 50% for liquid based cytology samples, eliminating manual preparation steps and improving workflow efficiency

PLEASANTON, California -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the cobas p 480 preanalytics instrument for automated uncapping and recapping of primary sample vials used for liquid-based cytology (LBC) and molecular assays run on the cobas® 4800 System.  For assays such as the cobas® HPV and cobas® CT/NG 4800 Test, the cobas p 480 instrument provides significant workflow and sample integrity advantages.  By addressing the need to automate sample preparation, the cobas p 480 helps to eliminate manual steps that can lead to repetitive motion injury, a significant area of concern for laboratory workers that handle a large number of samples each day.

Findings from an independent consulting firm show that when the p480 instrument is part of the workflow process, overall hands-on time for delivering test results from over 700 samples per day is reduced by up to 50%.  Preprocessing steps-- including: vial cap removal, vortexing and barcode quality checks-- are automated, reducing the risk of sample mix-up, cross contamination or user error and ensuring the reliability of test results.  The instrument allows primary vials to be loaded directly onto the cobas® 4800 System without a need to aliquot into a secondary vial.  New caps can be automatically re-placed on the primary vial for storage and post processing.

"For the first time, laboratories now have an option to directly load LBC primary vials for preanalytical and analytical processing through a combination of cobas® systems that support molecular testing," said Paul Brown, Head of Roche Molecular Diagnostics.  "We are proud to bring solutions to our laboratory partners that not only improve the quality of their test results but solutions that can improve the quality of life for their employees as well."

About the cobas® 4800 System
The cobas® 4800 System offers true walk-away automation of nucleic acid purification, PCR (polymerase chain reaction) set-up and real-time PCR amplification and detection to help laboratories achieve maximum efficiency.  The system runs the cobas® HPV Test, cobas® CT/NG Test (chlamydia/gonorrhea), cobas® BRAF V600 Mutation Test and the cobas® EGFR Mutation Test, along with an expanding menu of other molecular diagnostic tests.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned are protected by law.

For media inquiries please contact:
Bob Purcell
Vice President, Corporate Communications

Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


Post a comment about this story

(your e-mail address will not be posted)
Comment title:
To submit comment, enter the security code shown below and press 'Post Comment'.

 See related product stories
More .....
 See more product news in:
Laboratory and Research Supplies and Equipment
Machinery and Machining Tools
| Featured Manufacturing Jobs
 Other News from this company:
Roche Makes Offer to Acquire Ventana for $75.00 Per Share in Cash
International Census of Marine Microbes Reveals a Greater Level of Marine Diversity Using Ultrafast Sequencing System from Roche Diagnostics
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-mail this story to a friend
Save Story
Search for suppliers of
Laboratory Equipment & Supplies
Analytical Instruments
Vial Capping Machinery
Join the forum discussion at:
Tools of the Trade

Home  |  My ThomasNet News®  |  Industry Market Trends®  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by        Browse ThomasNet Directory

Copyright © 2014 Thomas Publishing Company. All Rights Reserved.
Terms of Use - Privacy Policy

Error close

Please enter a valid email address